Background: The last decade has seen a rapid growth in the number of clinical trials
| INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized
as an important public health problem and a major cause of liver disease. Nonalcoholic steatohepatitis (NASH), a subset of NAFLD with a higher likelihood of progression to advanced liver disease, is presently the most common cause of chronic liver disease (CLD) and a leading indication for liver transplantation in Western countries. [1] [2] [3] Over the last decade, there has been an acceleration in the search for new therapies for NASH and the number of clinical trials enrolling NASH and NAFLD patients is growing rapidly. 4, 5 Simultaneously, the inclusion of patients with NAFLD/NASH into clinical trials in therapeutic areas other than NASH is increasing and will likely continue to increase as the obesity epidemic expands worldwide. For example, the search for new drugs for treatment of type 2 diabetes mellitus (T2DM) has led to a myriad of clinical trials enrolling T2DM
patients that may have NAFLD in 60%-80% of the cases. 6, 7 As in other clinical trials, drug-induced liver injury (DILI) remains a major concern for drug developers and investigators in NASH trials. The well-recognized challenges in detection, assessment and management of DILI during drug development are amplified by the fact that a significant part of the target population may have varying degrees of hepatic fibrosis. However, there are no regulatory guidelines and position papers to provide information regarding DILI-related best practices for clinical trials enrolling patients with pre-existing NASH.
As a result, clinical investigators and drug developers face considerable uncertainty when identifying and managing suspected DILI in these trials, and often use diverse approaches and practices for assessment and management of liver safety signals. Given the enormous prevalence of CLD related to NASH worldwide, and the growing number of clinical trials assessing new drugs for NASH, there is a great unmet need for consistent, evidence-based recommendations for best practices pertaining to suspected DILI in such patients.
The IQ DILI Initiative was launched in June 2016 within the International Consortium for Innovation and Quality in Pharmaceutical Development (also known as the IQ consortium) to reach consensus and propose best practices on topics related to clinical DILI. 8 The IQ Consortium is a science-focused, not-for-profit organisation addressing scientific and technical aspects of drug development and is comprised of 39 pharmaceutical and biotechnology companies.
The IQ-DILI Initiative is an affiliate of the IQ Consortium, comprised of 15 IQ member companies, focused on establishing best practices for monitoring, diagnosing, managing and preventing DILI. This publication is based on an extensive literature review, and the consensus achieved in carefully structured discussions between IQ DILI members and academic and regulatory experts. The recommendations are based on the opinions of the authors, and do not imply a regulatory mandate. Although this publication focuses on DILI assessment during drug development, post-approval pharmacovigilance is an important part of the safety assessment of a new drug. This is especially important for assessment of DILI, which tends to be uncommon and might be missed during drug development. Most of the recommendations and best practices included in this publication are specific to acute hepatocellular DILI. It is well recognized that some drugs may cause other types of acute DILI including cholestatic liver injury, mixed hepatocellular-cholestatic and acute steatosis with metabolic acidosis. It is also recognized that drugs may cause chronic liver injury including hepatic fibrosis, steatosis, steatohepatitis, cirrhosis, nodular regenerative hyperplasia, and vascular diseases. 9 Cholestatic DILI will be discussed in detail in another paper by the IQ DILI initiative. Due to the scarcity of data in the published literature, other types of acute DILI and chronic DILI will not be discussed in this paper. However, it is strongly recommended that drug developers and investigators remain mindful of these less common types of DILI that could arise during drug development.
| ARE NAFLD PATIENTS SUSCEPTIBLE TO D ILI?
Whether patients with pre-existing liver disease including NAFLD are more susceptible to DILI compared to individuals with healthy livers is still a matter of ongoing debate. Zimmerman was the first to opine that most drugs could be safely given to patients with underlying liver disease, although he recognized that if acute injury occurred, the outcome in such patients could be dire. 10, 11 Evidence in the medical literature concerning the specific risk of DILI in patients with NAFLD is limited and conflicting. While one study reported that NAFLD significantly increased the risk of DILI in middle-aged men, compared to men with hepatitis C, 12 several other reports have supported the safety of statins [13] [14] [15] [16] [17] and of rosiglitazone 18 in patients with NAFLD. In some of these studies, small sample sizes or significant methodologic issues limit the validity of these observations. Furthermore, the extremely low incidence of clinically significant statin-related liver injury in the general population makes it difficult to assess the specific effect of pre-existing NAFLD. 19, 20 Nevertheless, based on the available evidence, there is a strong consensus that statins are safe in patients with NAFLD. 21 Several studies have demonstrated an association between NAFLD and increased activity of cytochrome P450 2E1 (CYP2E1). 22, 23 Since CYP2E1 plays a central role in the pathogenesis of acetaminopheninduced liver injury, the question of increased susceptibility of NAFLD patients to DILI due to acetaminophen overdose has been raised, although never examined directly. In studies of human liver samples, steatosis was associated with decreased hepatic cytochrome P450 3A (CYP3A) activity, and there appeared to be a relationship between the severity of hepatic steatosis and decreased CYP3A activity. 22, 24 Hepatic CYP3A is an important subfamily of drug-metabolizing enzymes that contributes to drug activation and to the control of endogenous hormone turnover; however, so far there is no evidence to suggest an association between decreased activity of CYP3A in NAFLD patients and DILI. Among authorities in the field of DILI there is still a general opinion that patients with CLD including NAFLD are not prone to develop DILI compared to the general population. [25] [26] [27] However, it is also widely believed that patients with pre-existing CLD are at higher risk for complicated REGEV ET AL.
| 703 course and adverse outcomes from DILI. [25] [26] [27] [28] A recent paper from the US Drug Induced Liver Injury Network (DILIN) showed that DILI in patients with pre-existing liver disease was associated with significantly higher frequency of adverse outcomes, including mortality.
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The pre-existing CLDs were mainly hepatitis C and NAFLD or unexplained elevations in liver biochemistries. The extent to which workup should be performed prior to enrolment to exclude other diagnoses has not been clearly defined. Based on published clinical guidelines it has been recommended that at a minimum, a thorough medical history should be taken, including detailed alcohol consumption information, and serological tests for hepatitis B, C and AIH be performed prior to enrolment. In addition,
NASH clinical trials often screen for HIV and exclude patients with positive HIV tests. 35, 59, 60 Other tests such as iron studies, anti-mitochondrial antibody and evaluation for α1 antitrypsin deficiency or
Wilson disease, should be considered based on the nature of the hepatic biochemical tests abnormality, the investigator's clinical judgement, and published guidance for clinical practice. 58, 61 Most NASH clinical trials have excluded patients with a history of significant alcohol use, aiming to avoid a mixed population of NASH and alcoholic liver disease. Cut-off levels for exclusion vary between trials and have included 14-21 standard drinks per week for men and 7-14 standard drinks per week for women. 33-35,47,62-,64 A standard drink contains roughly 14 g of pure alcohol, which is equivalent to a 12-ounce beer, a 4-ounce glass of wine or a 1-ounce shot of hard liquor. It should be noted that the National Institute on Alcohol
Abuse and Alcoholism (NIAAA) defines heavy or at-risk drinking as more than four standard drinks on any day or more than 14 drinks per week in men or more than three drinks on any day or seven drinks per week in women. 65 There is insufficient evidence to support the notion that patients who consume excessive alcohol are prone to develop DILI, but it is well established that patients who consume large quantities of alcohol are more likely to develop alcoholic liver disease, which may be difficult to differentiate from DILI. 5. HIV infected patients should generally be excluded and need to be studied separately. This recommendation does not apply to studies aiming to enrol patients with hepatic decompensation.
9.
Patients with elevated ALP, equal to or higher than 2× ULN or 250 U/L, should generally be excluded, unless the ALP elevation is not from a hepatic origin. criteria it is important to take into consideration the degree of variation that exists for ALT reference ranges between laboratories,
| MONITORING OF LIVER TESTS AND DILI DETECTION IN NASH CLINICAL TRIALS
where ULN values may vary between less than 30 U/L for some laboratories to more than 70 U/L for others. 71, 72 How to determine baseline ALT is also a matter of debate. Since in patients with NASH, ALT levels can fluctuate even over a short period, a single measurement on a given day may not represent a true baseline. It has been suggested to take at least two ALT measurements prior to enrolment (at least 2 weeks apart) and use the average of the two values as the most appropriate baseline. 55, 70 These measurements can be performed at the "screening visit" (typically visit 1) and the "baseline visit" (typically visit 2 or 3). In cases of significant changes between two measurements (for example, >50% difference), it has been suggested to obtain a third measurement for a better estimate of the magnitude and trend of the ALT changes. 70 If a patient exhibits a sharp change prior to enrolment, it would be preferable to hold enrolment until the underlying cause is identified or ALT levels stabilize. This approach may be time consuming and may not be feasible for all clinical trials. To harmonise and simplify the definition of "elevated baseline ALT" some authors have recommended to use ALT >1.5× ULN as an empiric threshold (see Table 1 ). 70 As demonstrated in several studies, AT levels may decrease during the treatment period in response to NASH treatment or life style modifications. 33, 35, 47, 63 T Baseline ALT is derived from an average of two pre-treatment ALT measurements at least 2 weeks apart. Elevated baseline is defined as ALT ≥1.5× ULN. In patients with a sizable stable decrease in ALT (>50% of the baseline value) during treatment, a new baseline, corresponding to the ALT nadir, should be established on an individual basis for subsequent determination of a DILI signal. The actions of close observation, monitoring, and drug interruption often overlap. Occasionally, workup is initiated after drug interruption. 
| Consensus and Recommendations
11.
In patients with normal or near normal baseline ALT, a combination of ALT ≥3×ULN plus TBL ≥2×ULN* or ALT ≥3×ULN plus hepatic symptoms should be considered as a signal of potential DILI (Table 1) .
12.
In patients with elevated baseline ALT (≥1.5×ULN), ALT elevation of >3× baseline or greater than 300 U/L (whichever comes first), even in the absence of hepatic symptoms or elevated TBL, is a reasonable threshold to suspect DILI and to initiate close observation and monitoring ( Table 1 ). The threshold values may need to be adjusted based on nonclinical data, mechanism of action or hepatic safety signals in early-phase trials.
13.
In patients with elevated baseline ALT (≥1.5× ULN), a combination of ALT ≥2× baseline or ALT ≥300×ULN (whichever comes first) plus TBL ≥2×ULN* or hepatic symptoms, should be considered as a signal of potential DILI and require interruption of the study drug (Table 1) .
14.
In patients who meet the criteria for a DILI signal, assessment for hepatic symptoms and liver tests should be repeated within 2-5 days. The specific interval between the tests should be determined based on the patient's clinical condition.
15.
Baseline values of ALT may need to be established based on an average of two consecutive tests performed at least 2 weeks apart prior to enrolment (preferably during the screening and baseline visits). If there is change in ALT level of >50% between the two tests, it may be prudent to perform a third test to determine the direction of the change, and to avoid enrolment until the cause is identified and ALT level stabilizes.
16.
In patients with a sizable stable decrease in ALT level during treatment (>50% of the baseline value), a new baseline, corresponding to the ALT nadir, may need to be established for subsequent determination of a DILI signal.
When designing liver-related monitoring and stopping rules, it is
important to take into consideration the variation of normal ALT range that exists among laboratories.
(*Does not apply to patients with Gilbert's syndrome.)
| SPECIAL CONSIDERATIONS FOR CAUSALITY ASSESSMENT OF SUSPECTED DILI IN PATIENTS WITH NASH
Causality assessment for suspected DILI is usually challenging during drug development, in part because there is insufficient information on the hepatic safety profile of the drug, and it is often unknown whether a study subject is receiving the active drug or placebo. 75, 76 The difficulty increases when study subjects have pre-existing liver disease such as NASH, which may lead to fluctuation in hepatic biochemical tests. 9 Causality assessment is required in NASH patients who meet the criteria for suspected DILI during a clinical trial ( 
21.
It is recommended to measure autoantibody titres (ANA and ASMA) prior to enrolment, to provide a baseline for subsequent comparison.
Elevated ferritin levels may be encountered in patients with
NAFLD. This finding should not automatically prompt evaluation for iron overload unless associated with an elevated transferrin saturation.
Emergence of ALP ≥2×ULN is not typical of NASH and should
prompt an evaluation for alternative aetiology including DILI. Hy's law is currently the most specific tool available to the pharmaceutical industry and regulatory agencies for assessing a drug's potential to cause severe hepatocellular DILI. 10, 11 Its predictive value has been validated in DILI registries from Sweden, 88 Spain 89 and the US, 90 where the risk of death or need for liver transplantation from acute DILI causing jaundice, approximates 10%. 10, 11 The current definition of Hy's law 10, 11 was intended to be applied in patients without underlying liver disease and thus presents a significant challenge when dealing with patients with NASH.
| ASSESSMENT OF DILI RISK DURING DRUG DEVELOPMENT IN PATIEN TS WITH NASH
According to current guidelines, a Hy's law case is defined by (a)
ALT elevation ≥3× ULN; (b) TBL ≥2× ULN; (c) absences of significant cholestasis; and (d) no other cause explaining the elevation of ALT and TBL. In addition, the suspected drug should show a higher incidence of ALT >3× ULN compared to the control drug or placebo. 69 Yet, in studies enrolling patients with NASH, ALT elevation may be related to the underlying NASH and thus the test abnormalities may not meet the definition of Hy's law. As a result, the predic- 
| HEPATIC DISCONTIN UATION RULES
In most idiosyncratic DILI cases, the only effective treatment is discontinuation of the causal agent. Delayed discontinuation can result in irreversible liver failure and death. 10, 90 On the other hand, automatic discontinuation of a study drug upon finding a mild abnormality in liver enzymes (eg elevation of ALT or AST to >3× 69 However, in some patients with NASH, ALT and AST may approach or cross these levels at baseline or during the trial, which may lead to premature discontinuations if these same stopping rules are applied. [32] [33] [34] [35] Several experts have suggested that in patients with NASH enrolled in clinical trials with elevated ALT, AST or TBL, discontinuation rules should be determined as multiples of baseline rather than multiples of ULN. 30, 70 For example, it has been suggested that in patients with NASH enrolled with elevated ALT discontinuation should be considered for ALT levels exceeding 5× baseline or 500 U/L (whichever occurs first) ( Table 1) .
Concurrent elevation of ALT and TBL should be viewed as a more specific indication of severe DILI and should lead to an earlier discontinuation. In such cases, patients who had normal TBL and ALT of ≥1.5× ULN at baseline, may need to be considered for discontinuation when ALT is ≥2× baseline, if TBL increases to ≥2× ULN (Table 1) . Of note: Occasionally in clinical trials the study drug has to be interrupted, but can then be resumed when a clear cause of liver injury other than the drug is identified and liver enzymes improve.
| Consensus and Recommendations
28.
When considering study drug discontinuation in NASH patients with suspected DILI, who had elevated baseline ALT (≥1.5×ULN), it is recommended to assess the change from baseline rather than the change from ULN (Table 1) .
29.
In patients with normal baseline ALT and TBL, study drug discontinuation should conform to the current FDA stopping rules: | 709 nadir should be considered as the new baseline for monitoring and discontinuation decisions.
32.
Occasionally, the study drug has to be interrupted because of acute biochemical changes, but can then be resumed when a clear cause other than the drug is identified, and liver enzymes improve.
| BIOMARKE RS FOR D ETECTION AND ASSESSMENT OF DILI IN PATIENTS WITH NASH
Despite intensive efforts to identify and develop new noninvasive biomarkers for detection and assessment of DILI, none of these future biomarkers is qualified or ready for routine use. Ongoing 
| MONITORING AND ASSESSMENT OF DILI IN CIRRHOTIC NASH PATIENTS WITH OR WITHOUT HEPATIC DECOMPENSATION
While a complete discussion of the assessment and management of DILI occurring in patients with cirrhotic NASH is beyond the scope of this paper, a few points will be briefly addressed. Monitoring and assessment of DILI in patients with cirrhosis present drug developers and clinical investigators with unique challenges, which to date have not been addressed in existing regulatory guidance. It should be noted that patients with advanced liver disease can have normal AT values or only mild elevations. Importantly, the AST:ALT ratio may increase to >1 in such patients, and the ratio may increase as the disease progresses. 95 In general, DILI in patients with preexisting liver dysfunction may sometimes present with rapid deterioration of liver function (ie elevated direct bilirubin and prolonged INR), with only mild changes in ATs. [96] [97] [98] Therefore, close monitoring is essential in such patients, to enable early detection of the first signs of DILI, and ensure early discontinuation of the drug. Such patients are often highly confounded and causality assessment may be very challenging.
To date there are no published systematic reports of drug treatment in patients with NASH-related advanced liver disease or decompensated cirrhosis, although clinical trials are ongoing. In fact, relatively few publications discuss the management of DILI patients with preexisting liver dysfunction who participate in clinical trials.
55,70
| SUMMARY
The number of drug-development programs for NASH has grown considerably over the last decade. Moreover, the inclusion of patients with diagnosed or undiagnosed NASH into trials in other therapeutic areas is increasing rapidly, and will likely continue to increase as the obesity and diabetes epidemic expands worldwide.
There is a great need for consistent and evidence based recommendations for best practices to enable better monitoring, assessment, and management of suspected DILI in patients with NASH. This paper provides a framework for recommendations based on the collaborative work of the IQ DILI initiative with experts from academia and other experts in the DILI field. 
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